Search

EHA-Balkan Hematology Tutorial on Lymphoid Malignancies

“EHA and the Albanian Association of Hematology have jointly decided to postpone the first EHA-Balkan Hematology Tutorial in response to a request from the Albanian government to limit all international meetings.

Read more

Privacy statement

May 21, 2021

Privacy Statement European Hematology Association

Personal Data is processed in the context of the services provided by European Hematology Association (hereinafter also; “EHA”).

Read more

What to expect

FacultyThe faculty is made up of international leaders in clinical hematology research, statisticians, experts in regulatory and ethical aspects of clinical research and more.

Read more

Code of Conduct

The guidelines below govern the publication of, and commentary on the EHA Hematology Hub. Please read through them before participating. 1. Abide by the rules that normally apply.

Read more

EHA-SSH Joint membership

We are pleased to inform that EHA and the Swiss Society of Hematology (SSH) have joined forces and are offering you the possibility of an EHA-SSH Joint Membership in 2023.

Read more

Guidelines for hematologists

For guidance regarding COVID-19, see FAQ by the EHA SWG on Infections

EHA creates clinical practice guidelines for diagnosis and treatment of hematologic diseases.

Read more

EHA-HSHT Joint Membership

Join EHA and HSHT to receive up to €50 discount on your membershipThe European Hematology Association (EHA) and the Hungarian Society of Hematology and Transfusion (HSHT) - Magyar Hematológiai és Transzfuziológiai Társaság – MHTT, have joined forces to offer joint membership to…

Read more

Parliament puts final stamp on the European Health Data Space

On April 24, the European Parliament gave its final endorsement to the regulation on the European Health Data Space (EHDS). The legislation was proposed in May 2022, and constitutes an important pillar of the (developing) European Health Union.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more